MELBOURNE, Australia, April 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announces the closing of its previously announced registered offering for the purchase and sale of 1,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents in... Read More

MELBOURNE, Australia, April 19, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, "Company", "GTG", or "Genetic Technologies"), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of 1,000,000 American Depositary Shares ("ADSs") (or... Read More

MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has established a precision oncology division and announced its highly anticipated portfolio of new diagnostic tests under its geneType precision oncology brand. The... Read More

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the company’s latest milestones along with our clinical adoption of the Company’s groundbreaking geneType Risk Assessment Tests routinely across 12 states in the United States and nationally in... Read More

MELBOURNE, Australia, April 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the company is establishing a clinical implementation study with breast imaging centers across New York, Miami and Houston. The initiative will pilot the integration of the geneType into breast... Read More

MELBOURNE, Australia, April 08, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce an innovative partnership between GTG, and Humanise Health launching a "Know Your Risk" event featuring the company’s unique Risk Assessment portfolio, to be held at The Langham, Pasadena,... Read More

MELBOURNE, Australia, April 02, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to report the company’s new digital strategy, led by the company’s recently appointed strategic advisor, Dr. Malcolm Bohm, is having a significant positive impact across all facets of GTG’s social media... Read More

MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation. This innovation is driven by: Strong global academic relationships with research groups Continuous development of the geneType portfolio A... Read More

MELBOURNE, Australia, March 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”, “GENE”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to announce the development of the Company’s most advanced risk assessment test for serious diseases, building on the success of the Comprehensive Hereditary Breast and Ovarian Cancer (HBOC) test.... Read More

MELBOURNE, Australia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), is pleased to announce the launch of a wide-reaching customer – targeted digital advertising campaign in the United States. This comprehensive program will drive Consumer Initiated Testing (CIT) for the company’s geneType Risk Assessment Tests. The campaign will commence end of March 2024 and will scale up... Read More

MELBOURNE, Australia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE), is at the forefront in personalised predictive genomics, reshaping the healthcare landscape with its inventive strategy for early disease detection and personalized wellness is pleased to share Business update for the quarter ending 31 December 2023 (Q2 FY24). GENE's pioneering initiatives in genomics-based tests place it at... Read More

MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests in health, wellness, and serious disease, advises that it has received formal notice from the Nasdaq Stock Market, LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). As previously... Read More

MELBOURNE, Australia, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies (GTG) is proud to provide details of a series of recent transformative initiatives. Our commitment to advancing early detection of serious diseases through a revolutionary non-invasive saliva test has been recently showcased on several national Australian media channels. These segments highlight geneType's potential to shape the future of proactive... Read More

MELBOURNE, Australia, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, announced today its plans to effect: (i) a share consolidation of its ordinary shares (the “Shares”) of one (1) for one hundred (100) existing Shares (the “Local Consolidation”) and (ii) a change of ratio in the... Read More

MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to provide an update on the company activities for the quarter ending 30 September 2023. Highlights : Partnership signed with the Gold Coast Private Hospital (a member of Healthscope), to... Read More

MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of a peer-reviewed research paper validating geneType’s Pancreatic Cancer risk assessment test. Highlights: Pancreatic cancer has a very high mortality rate, approximately 76% 1... Read More

MELBOURNE, Australia, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce a partnership with the Gold Coast Private Hospital (GCPH), a member of Healthscope, to... Read More

Genetic Technologies Limited Expands Reach of Revolutionary geneType Multi-Risk Test in Australia: A major advancement towards preventative Healthcare MELBOURNE, Australia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (GTG), a pioneering global leader in genomics-based tests focused on health, wellness, and the battle against serious diseases, proudly announces a groundbreaking development. The expanded... Read More

MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce that a Medical Research Future Fund (MRFF) Genomics Health Futures Mission Grant has been awarded to a group of renowned national and international research and charity organizations. The grant... Read More

MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to advise that RedChip Companies will air interviews with Genetic Technologies Limited (Nasdaq: GENE) and 60 Degrees Pharmaceuticals (60P) (NASDAQ: SXTP) on The RedChip Money Report ® , a... Read More

MELBOURNE, Australia, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to report annual results for the year ended June 30, 2023. GTG has had an exciting period of commercial growth over the last 12 months in our Business to Business (B2B) channel led by... Read More

MELBOURNE, Australia, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG, “Company”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to provide an update on the company’s activities via the latest investor presentation attached. Enquiries Investor Relations Adrian Mulcahy Automic Markets M: +61 438 630 411 E: adrian.mulcahy@automicgroup.com.au... Read More

MELBOURNE, Australia, July 28, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to provide this Quarterly Business Update for the quarter ending 30 June 2023. Highlights : June... Read More

MELBOURNE, Australia, July 21, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests in health, wellness and serious disease, advises that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq... Read More

MELBOURNE, Australia, May 23, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce that the Company’s geneType Breast Cancer Risk Assessment Test featured on “The Balancing Act”... Read More

MELBOURNE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the publication of a research paper in the peer-reviewed journal Melanoma Research validating the geneType for Melanoma risk assessment test in one of the most commonly diagnosed cancers in the... Read More

MELBOURNE, Australia, April 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C and Quarterly business update for the quarter ending 31 March 2023 (Q3 FY23). Highlights : Announced the development of the world’s first Comprehensive Breast & Ovarian... Read More

MELBOURNE, Australia, April 19, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the publication of a research paper in “The Prostate” validating the utilisation of geneType Prostate Cancer Risk Assessment Test in the identification of men who are at increased risk of this... Read More

MELBOURNE, Australia, March 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the US launch of three (3) new diseases taking the total number of individual risk assessments included in the geneType Multi-Test to nine (9), all from the one simple saliva sample. This... Read More

MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of another research paper supporting the utilisation of geneType Breast Cancer Risk Assessment Test in the peer-reviewed journal Cancer Prevention Research. Highlights: 2 nd... Read More

MELBOURNE, Australia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the publication of a new research paper in the peer-reviewed journal Breast Cancer Research and Treatment. Highlights: GeneType outperforms 5-year and remaining lifetime risk prediction... Read More

MELBOURNE, Australia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced the closing of its previously announced registered direct offering with several institutional investors for the purchase and sale of 3,846,155 American... Read More

MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is delighted to provide further update. The innovation and development of this test is inspired by direct response and feedback from the payer conversations such as insurance providers, employers, and healthcare... Read More

MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 3,846,155... Read More

MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company will launch a ‘World First’ Comprehensive Risk Assessment Test which evaluates a women’s risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or... Read More

MELBOURNE, Australia, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to announce that the Company is forming a strategic alliance with QIAGEN, a global leader in molecular testing with operations in 35 countries. The alliance will establish and develop a... Read More

MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,” Company”, “GTG”), a global leader in guidance-driven genomics-based tests in health, wellness and serious diseases releases its Quarterly business update for the quarter ended 31 December 2022 (Q2 FY23). Highlights: Qtr... Read More

MELBOURNE, Australia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce a poster presentation by Dr Erika Spaeth at the prestigious American Society of Clinical Oncology Gastroenterology Cancer Symposium in San Francisco last weekend. The Poster titled “... Read More

MELBOURNE, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,”Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to provide the following business update for the first half of the 2023 financial year. Operating in the multibillion dollar predictive and consumer genomics markets, GTG has achieved five... Read More